{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:41:41Z","timestamp":1794663701856,"version":"4.9.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41584-023-01021-4","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:02:50Z","timestamp":1694430170000},"page":"613-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Placebo effects in osteoarthritis: implications for treatment and drug development"],"prefix":"10.1038","volume":"19","author":[{"given":"Tuhina","family":"Neogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-4709","authenticated-orcid":false,"given":"Luana","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/art.42089","volume":"74","author":"H Long","year":"2022","unstructured":"Long, H. et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the Global Burden of Disease Study 2019. Arthritis Rheumatol. 74, 1172\u20131183 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745\u20131759 (2019).","journal-title":"Lancet"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2019-215142","volume":"78","author":"E Sebbag","year":"2019","unstructured":"Sebbag, E. et al. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization burden of diseases database. Ann. Rheum. Dis. 78, 844\u2013848 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3899\/jrheum.170990","volume":"46","author":"JA Singh","year":"2019","unstructured":"Singh, J. A., Yu, S., Chen, L. & Cleveland, J. D. Rates of total joint replacement in the United States: future projections to 2020\u20132040 using the national inpatient sample. J. Rheumatol. 46, 1134\u20131140 (2019).","journal-title":"J. Rheumatol."},{"key":"1021_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17228","volume":"2","author":"A Stokes","year":"2019","unstructured":"Stokes, A., Berry, K. M., Hempstead, K., Lundberg, D. J. & Neogi, T. Trends in prescription analgesic use among adults with musculoskeletal conditions in the united states, 1999\u20132016. JAMA Netw. Open 2, e1917228 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/annrheumdis-2012-202239","volume":"72","author":"MP Hellio le Graverand","year":"2013","unstructured":"Hellio le Graverand, M. P. et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann. Rheum. Dis. 72, 187\u2013195 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1002\/art.22160","volume":"54","author":"CO Bingham III","year":"2006","unstructured":"Bingham, C. O. III et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 54, 3494\u20133507 (2006).","journal-title":"Arthritis Rheum."},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","volume":"23","author":"MA Karsdal","year":"2015","unstructured":"Karsdal, M. A. et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 23, 532\u2013543 (2015).","journal-title":"Osteoarthritis Cartilage"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.7326\/M19-0675","volume":"172","author":"PG Conaghan","year":"2020","unstructured":"Conaghan, P. G. et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized controlled trial. Ann. Intern. Med. 172, 86\u201395 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.joca.2018.11.002","volume":"27","author":"VB Kraus","year":"2019","unstructured":"Kraus, V. B. et al. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA\u2019s accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthritis Cartilage 27, 571\u2013579 (2019).","journal-title":"Osteoarthritis Cartilage"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2019.14735","volume":"322","author":"MC Hochberg","year":"2019","unstructured":"Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. J. Am. Med. Assoc. 322, 1360\u20131370 (2019).","journal-title":"J. Am. Med. Assoc."},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/M15-0623","volume":"163","author":"RR Bannuru","year":"2015","unstructured":"Bannuru, R. R. et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163, 365\u2013372 (2015).","journal-title":"Ann. Intern. Med."},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/ard.2008.092015","volume":"67","author":"W Zhang","year":"2008","unstructured":"Zhang, W., Robertson, J., Jones, A. C., Dieppe, P. A. & Doherty, M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 67, 1716\u20131723 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.joca.2022.12.011","volume":"31","author":"M Henriksen","year":"2023","unstructured":"Henriksen, M. et al. Exercise and education vs intra-articular saline for knee osteoarthritis: a 1-year follow-up of a randomized trial. Osteoarthritis Cartilage 31, 627\u2013635 (2023).","journal-title":"Osteoarthritis Cartilage"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.joca.2023.02.001","volume":"31","author":"M Englund","year":"2023","unstructured":"Englund, M. & Turkiewicz, A. The emperor\u2019s new clothes. Osteoarthritis Cartilage 31, 549\u2013551 (2023).","journal-title":"Osteoarthritis Cartilage"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","volume":"59","author":"L Colloca","year":"2019","unstructured":"Colloca, L. The placebo effect in pain therapies. Annu. Rev. Pharmacol. Toxicol. 59, 191\u2013211 (2019).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca, L. & Barsky, A. J. Placebo and nocebo effects. N. Engl. J. Med. 382, 554\u2013561 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-pharmtox-052120-104536","volume":"62","author":"F Benedetti","year":"2022","unstructured":"Benedetti, F., Frisaldi, E. & Shaibani, A. Thirty years of neuroscientific investigation of placebo and nocebo: the interesting, the good, and the bad. Annu. Rev. Pharmacol. Toxicol. 62, 323\u2013340 (2022).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.neuron.2014.10.023","volume":"84","author":"F Benedetti","year":"2014","unstructured":"Benedetti, F. Placebo effects: from the neurobiological paradigm to translational implications. Neuron 84, 623\u2013637 (2014).","journal-title":"Neuron"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","volume":"25","author":"F Benedetti","year":"2005","unstructured":"Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S. & Zubieta, J. K. Neurobiological mechanisms of the placebo effect. J. Neurosci. 25, 10390\u201310402 (2005).","journal-title":"J. Neurosci."},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-662-44519-8_10","volume":"225","author":"L Wendt","year":"2014","unstructured":"Wendt, L., Albring, A. & Schedlowski, M. Learned placebo responses in neuroendocrine and immune functions. Handb. Exp. Pharmacol. 225, 159\u2013181 (2014).","journal-title":"Handb. Exp. Pharmacol."},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.irn.2018.01.001","volume":"138","author":"M Hadamitzky","year":"2018","unstructured":"Hadamitzky, M., Sondermann, W., Benson, S. & Schedlowski, M. Placebo effects in the immune system. Int. Rev. Neurobiol. 138, 39\u201359 (2018).","journal-title":"Int. Rev. Neurobiol."},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/art.41101","volume":"72","author":"L Luckemann","year":"2020","unstructured":"Luckemann, L., Stangl, H., Straub, R. H., Schedlowski, M. & Hadamitzky, M. Learned immunosuppressive placebo response attenuates disease progression in a rodent model of rheumatoid arthritis. Arthritis Rheumatol. 72, 588\u2013597 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1021_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00006842-197507000-00007","volume":"37","author":"R Ader","year":"1975","unstructured":"Ader, R. & Cohen, N. Behaviorally conditioned immunosuppression. Psychosom. Med. 37, 333\u2013340 (1975).","journal-title":"Psychosom. Med."},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00004703-199204000-00008","volume":"13","author":"K Olness","year":"1992","unstructured":"Olness, K. & Ader, R. Conditioning as an adjunct in the pharmacotherapy of lupus erythematosus. J. Dev. Behav. Pediatr. 13, 124\u2013125 (1992).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1176\/jnp.8.2.194","volume":"8","author":"DW Giang","year":"1996","unstructured":"Giang, D. W. et al. Conditioning of cyclophosphamide-induced leukopenia in humans. J. Neuropsychiatry Clin. Neurosci. 8, 194\u2013201 (1996).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"1021_CR27","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1096\/fj.02-0389com","volume":"16","author":"MU Goebel","year":"2002","unstructured":"Goebel, M. U. et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 16, 1869\u20131873 (2002).","journal-title":"FASEB J."},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-662-44519-8_2","volume":"225","author":"L Colloca","year":"2014","unstructured":"Colloca, L. Placebo, nocebo, and learning mechanisms. Handb. Exp. Pharmacol. 225, 17\u201335 (2014).","journal-title":"Handb. Exp. Pharmacol."},{"key":"1021_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1098\/rstb.2010.0398","volume":"366","author":"L Colloca","year":"2011","unstructured":"Colloca, L. & Miller, F. G. How placebo responses are formed: a learning perspective. Phil. Trans. R. Soc. B 366, 1859\u20131869 (2011).","journal-title":"Phil. Trans. R. Soc. B"},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/YCO.0b013e328343803b","volume":"24","author":"L Colloca","year":"2011","unstructured":"Colloca, L. & Miller, F. G. Role of expectations in health. Curr. Opin. Psychiatry 24, 149\u2013155 (2011).","journal-title":"Curr. Opin. Psychiatry"},{"key":"1021_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jpain.2022.12.011","volume":"24","author":"DJ Langford","year":"2022","unstructured":"Langford, D. J. et al. Expectations for improvement: a neglected but potentially important covariate or moderator for chronic pain clinical trials. J. Pain\u00a024, 575\u2013581 (2022).","journal-title":"J. Pain"},{"key":"1021_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002810","volume":"3","author":"M Gil","year":"2008","unstructured":"Gil, M., Menzel, R. & De Marco, R. J. Does an insect\u2019s unconditioned response to sucrose reveal expectations of reward?\u00a0PLoS ONE\u00a03, e2810 (2008).","journal-title":"PLoS ONE"},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000507400","volume":"89","author":"L Colloca","year":"2020","unstructured":"Colloca, L. et al. Prior therapeutic experiences, not expectation ratings, predict placebo effects: an experimental study in chronic pain and healthy participants. Psychother. Psychosom. 89, 371\u2013378 (2020).","journal-title":"Psychother. Psychosom."},{"key":"1021_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1474-4422(04)00908-1","volume":"3","author":"L Colloca","year":"2004","unstructured":"Colloca, L., Lopiano, L., Lanotte, M. & Benedetti, F. Overt versus covert treatment for pain, anxiety, and Parkinson\u2019s disease. Lancet Neurol. 3, 679\u2013684 (2004).","journal-title":"Lancet Neurol."},{"key":"1021_CR35","first-page":"S315","volume":"56","author":"M Suarez-Almazor","year":"2007","unstructured":"Suarez-Almazor, M. et al. A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of provider communication style. Arthritis Rheum. 56, S315 (2007).","journal-title":"Arthritis Rheum."},{"key":"1021_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jpain.2017.12.260","volume":"19","author":"RL Gollub","year":"2018","unstructured":"Gollub, R. L. et al. A functional neuroimaging study of expectancy effects on pain response in patients with knee osteoarthritis. J. Pain\u00a019, 515\u2013527 (2018).","journal-title":"J. Pain"},{"key":"1021_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2018.01.021","volume":"18","author":"J Kong","year":"2018","unstructured":"Kong, J. et al. Enhancing treatment of osteoarthritis knee pain by boosting expectancy: a functional neuroimaging study. Neuroimage Clin. 18, 325\u2013334 (2018).","journal-title":"Neuroimage Clin."},{"key":"1021_CR38","doi-asserted-by":"publisher","first-page":"817179","DOI":"10.3389\/fpsyt.2022.817179","volume":"13","author":"S Rosenkjaer","year":"2022","unstructured":"Rosenkjaer, S., Lunde, S. J., Kirsch, I. & Vase, L. Expectations: how and when do they contribute to placebo analgesia. Front. Psychiatry 13, 817179 (2022).","journal-title":"Front. Psychiatry"},{"key":"1021_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/1740774512465064","volume":"9","author":"J Younger","year":"2012","unstructured":"Younger, J., Gandhi, V., Hubbard, E. & Mackey, S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin. Trials 9, 767\u2013776 (2012).","journal-title":"Clin. Trials"},{"key":"1021_CR40","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/ntr\/ntac187","volume":"24","author":"AC Ferkin","year":"2022","unstructured":"Ferkin, A. C. et al. A psychometric evaluation of the Stanford Expectations of Treatment Scale (SETS) in the context of a smoking cessation trial. Nicotine Tob. Res. 24, 1914\u20131920 (2022).","journal-title":"Nicotine Tob. Res."},{"key":"1021_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280472","volume":"18","author":"MC Shedden-Mora","year":"2023","unstructured":"Shedden-Mora, M. C. et al. The treatment expectation questionnaire (TEX-Q): validation of a generic multidimensional scale measuring patients\u2019 treatment expectations. PLoS ONE\u00a018, e0280472 (2023).","journal-title":"PLoS ONE"},{"key":"1021_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036169","volume":"10","author":"J Alberts","year":"2020","unstructured":"Alberts, J. et al. Development of the generic, multidimensional treatment expectation questionnaire (TEX-Q) through systematic literature review, expert surveys and qualitative interviews. BMJ Open\u00a010, e036169 (2020).","journal-title":"BMJ Open"},{"key":"1021_CR43","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1038\/s41586-023-05745-x","volume":"615","author":"T Spisak","year":"2023","unstructured":"Spisak, T., Bingel, U. & Wager, T. D. Multivariate BWAS can be replicable with moderate sample sizes. Nature 615, E4\u2013E7 (2023).","journal-title":"Nature"},{"key":"1021_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002570","volume":"14","author":"P Tetreault","year":"2016","unstructured":"Tetreault, P. et al. Brain connectivity predicts placebo response across chronic pain clinical trials. PLoS Biol. 14, e1002570 (2016).","journal-title":"PLoS Biol."},{"key":"1021_CR45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/j.pain.0000000000002450","volume":"163","author":"E Vachon-Presseau","year":"2022","unstructured":"Vachon-Presseau, E. et al. Validating a biosignature-predicting placebo pill response in chronic pain in the settings of a randomized controlled trial. Pain 163, 910\u2013922 (2022).","journal-title":"Pain"},{"key":"1021_CR46","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrneurol.2017.122","volume":"13","author":"KD Davis","year":"2017","unstructured":"Davis, K. D. et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nat. Rev. Neurol. 13, 624\u2013638 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1021_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroscience.2015.08.017","volume":"307","author":"B Colagiuri","year":"2015","unstructured":"Colagiuri, B., Schenk, L. A., Kessler, M. D., Dorsey, S. G. & Colloca, L. The placebo effect: from concepts to genes. Neuroscience 307, 171\u2013190 (2015).","journal-title":"Neuroscience"},{"key":"1021_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","volume":"21","author":"KT Hall","year":"2015","unstructured":"Hall, K. T., Loscalzo, J. & Kaptchuk, T. J. Genetics and the placebo effect: the placebome. Trends Mol. Med. 21, 285\u2013294 (2015).","journal-title":"Trends Mol. Med."},{"key":"1021_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.1180142","volume":"326","author":"F Eippert","year":"2009","unstructured":"Eippert, F., Finsterbusch, J., Bingel, U. & Buchel, C. Direct evidence for spinal cord involvement in placebo analgesia. Science 326, 404 (2009).","journal-title":"Science"},{"key":"1021_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fpsyt.2020.00039","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Modeling learning patterns to predict placebo analgesic effects in healthy and chronic orofacial pain participants. Front. Psychiatry 11, 39 (2020).","journal-title":"Front. Psychiatry"},{"key":"1021_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000958","volume":"6","author":"L Colloca","year":"2021","unstructured":"Colloca, L., Thomas, S., Yin, M., Haycock, N. R. & Wang, Y. Pain experience and mood disorders during the lockdown of the COVID-19 pandemic in the United States: an opportunistic study. Pain Rep. 6, e958 (2021).","journal-title":"Pain Rep."},{"key":"1021_CR52","doi-asserted-by":"publisher","first-page":"106734","DOI":"10.1016\/j.cct.2022.106734","volume":"116","author":"R Shafir","year":"2022","unstructured":"Shafir, R., Olson, E. & Colloca, L. The neglect of sex: a call to action for including sex as a biological variable in placebo and nocebo research. Contemp. Clin. Trials 116, 106734 (2022).","journal-title":"Contemp. Clin. Trials"},{"key":"1021_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/j.pain.0000000000002038","volume":"162","author":"EM Olson","year":"2021","unstructured":"Olson, E. M. et al. Effects of sex on placebo effects in chronic pain participants: a cross-sectional study. Pain 162, 531\u2013542 (2021).","journal-title":"Pain"},{"key":"1021_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/j.pain.0000000000002478","volume":"163","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Chan, E., Dorsey, S. G., Campbell, C. M. & Colloca, L. Who are the placebo responders? A cross-sectional cohort study for psychological determinants. Pain 163, 1078\u20131090 (2022).","journal-title":"Pain"},{"key":"1021_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1037\/a0020909","volume":"119","author":"CA Sanislow","year":"2010","unstructured":"Sanislow, C. A. et al. Developing constructs for psychopathology research: research domain criteria. J. Abnorm. Psychol. 119, 631\u2013639 (2010).","journal-title":"J. Abnorm. Psychol."},{"key":"1021_CR56","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel, T. et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167, 748\u2013751 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"1021_CR57","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1002\/art.38869","volume":"66","author":"RH Dworkin","year":"2014","unstructured":"Dworkin, R. H. et al. Meta-analysis of assay sensitivity and study features in clinical trials of pharmacologic treatments for osteoarthritis pain. Arthritis Rheumatol. 66, 3327\u20133336 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1021_CR58","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1097\/j.pain.0000000000001340","volume":"159","author":"NB Finnerup","year":"2018","unstructured":"Finnerup, N. B. et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain 159, 2339\u20132346 (2018).","journal-title":"Pain"},{"key":"1021_CR59","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.pain.2014.05.009","volume":"155","author":"JT Farrar","year":"2014","unstructured":"Farrar, J. T. et al. Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. Pain 155, 1622\u20131631 (2014).","journal-title":"Pain"},{"key":"1021_CR60","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/j.pain.0000000000001538","volume":"160","author":"R Treister","year":"2019","unstructured":"Treister, R., Honigman, L., Lawal, O. D., Lanier, R. K. & Katz, N. P. A deeper look at pain variability and its relationship with the placebo response: results from a randomized, double-blind, placebo-controlled clinical trial of naproxen in osteoarthritis of the knee. Pain 160, 1522\u20131528 (2019).","journal-title":"Pain"},{"key":"1021_CR61","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1097\/j.pain.0000000000001876","volume":"161","author":"C Okusogu","year":"2020","unstructured":"Okusogu, C. et al. Placebo hypoalgesia: racial differences. Pain 161, 1872\u20131883 (2020).","journal-title":"Pain"},{"key":"1021_CR62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/j.pain.0000000000002038","volume":"162","author":"EM Olson","year":"2020","unstructured":"Olson, E. M. et al. Effects of sex on placebo effects in chronic pain participants: a cross-sectional study. Pain 162, 531\u2013542 (2020).","journal-title":"Pain"},{"key":"1021_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/j.pain.0000000000000771","volume":"158","author":"RH Dworkin","year":"2017","unstructured":"Dworkin, R. H. & Edwards, R. R. Phenotypes and treatment response: it\u2019s difficult to make predictions, especially about the future. Pain 158, 187\u2013189 (2017).","journal-title":"Pain"},{"key":"1021_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamapsychiatry.2021.3963","volume":"79","author":"D Hohenschurz-Schmidt","year":"2022","unstructured":"Hohenschurz-Schmidt, D., Draper-Rodi, J. & Vase, L. Dissimilar control interventions in clinical trials undermine interpretability. JAMA Psychiatry 79, 271\u2013272 (2022).","journal-title":"JAMA Psychiatry"},{"key":"1021_CR65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/j.pain.0000000000002730","volume":"164","author":"D Hohenschurz-Schmidt","year":"2022","unstructured":"Hohenschurz-Schmidt, D. et al. Blinding and sham control methods in trials of physical, psychological, and self-management interventions for pain (article II): a meta-analysis relating methods to trial results. Pain 164, 509\u2013533 (2022).","journal-title":"Pain"},{"key":"1021_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00421-007-0593-6","volume":"102","author":"L Colloca","year":"2008","unstructured":"Colloca, L., Benedetti, F. & Porro, C. A. Experimental designs and brain mapping approaches for studying the placebo analgesic effect. Eur. J. Appl. Physiol. 102, 371\u2013380 (2008).","journal-title":"Eur. J. Appl. Physiol."},{"key":"1021_CR67","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1126\/science.183.4128.922","volume":"183","author":"HM Parsons","year":"1974","unstructured":"Parsons, H. M. What happened at Hawthorne?: new evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies. Science 183, 922\u2013932 (1974).","journal-title":"Science"},{"key":"1021_CR68","first-page":"28","volume":"1","author":"FC Ulmer","year":"1976","unstructured":"Ulmer, F. C. The Hawthorne effect. Educ. Dir. Dent. Aux. 1, 28 (1976).","journal-title":"Educ. Dir. Dent. Aux."},{"key":"1021_CR69","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S1474-4422(16)00066-1","volume":"15","author":"F Benedetti","year":"2016","unstructured":"Benedetti, F., Carlino, E. & Piedimonte, A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 15, 736\u2013747 (2016).","journal-title":"Lancet Neurol."},{"key":"1021_CR70","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jbspin.2011.06.001","volume":"78","author":"JM Berthelot","year":"2011","unstructured":"Berthelot, J. M., Le Goff, B. & Maugars, Y. The Hawthorne effect: stronger than the placebo effect. Jt. Bone Spine 78, 335\u2013336 (2011).","journal-title":"Jt. Bone Spine"},{"key":"1021_CR71","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pain.2009.01.033","volume":"144","author":"L Colloca","year":"2009","unstructured":"Colloca, L. & Benedetti, F. Placebo analgesia induced by social observational learning. Pain 144, 28\u201334 (2009).","journal-title":"Pain"},{"key":"1021_CR72","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3899\/jrheum.100497","volume":"37","author":"F Wolfe","year":"2010","unstructured":"Wolfe, F. & Michaud, K. The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. J. Rheumatol. 37, 2216\u20132220 (2010).","journal-title":"J. Rheumatol."},{"key":"1021_CR73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212910120","volume":"120","author":"DM Ellingsen","year":"2023","unstructured":"Ellingsen, D. M. et al. Brain-to-brain mechanisms underlying pain empathy and social modulation of pain in the patient-clinician interaction. Proc. Natl Acad. Sci. USA 120, e2212910120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1021_CR74","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bmj.311.7004.551","volume":"311","author":"E Ernst","year":"1995","unstructured":"Ernst, E. & Resch, K. L. Concept of true and perceived placebo effects. Br. Med. J. 311, 551\u2013553 (1995).","journal-title":"Br. Med. J."},{"key":"1021_CR75","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nrn1705","volume":"6","author":"L Colloca","year":"2005","unstructured":"Colloca, L. & Benedetti, F. Placebos and painkillers: is mind as real as matter? Nat. Rev. Neurosci. 6, 545\u2013552 (2005).","journal-title":"Nat. Rev. Neurosci."},{"key":"1021_CR76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2466\/pr0.1962.10.2.383","volume":"10","author":"S Ross","year":"1962","unstructured":"Ross, S., Krugman, A. D., Lyerly, S. B., Clyde & J, D. Drugs and placebos: a model design. Psychol. Rep. 10, 383\u2013392 (1962).","journal-title":"Psychol. Rep."},{"key":"1021_CR77","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1037\/0735-7044.102.2.319","volume":"102","author":"I Kirsch","year":"1988","unstructured":"Kirsch, I. & Weixel, L. J. Double-blind versus deceptive administration of a placebo. Behav. Neurosci. 102, 319\u2013323 (1988).","journal-title":"Behav. Neurosci."},{"key":"1021_CR78","doi-asserted-by":"publisher","first-page":"1a","DOI":"10.1037\/1522-3736.6.1.61a","volume":"6","author":"F Benedetti","year":"2003","unstructured":"Benedetti, F. et al. Open versus hidden medical treatments: the patient\u2019s knowledge about a therapy affects the therapy outcome. Prev. Treat. 6, 1a (2003).","journal-title":"Prev. Treat."},{"key":"1021_CR79","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainresbull.2004.01.010","volume":"63","author":"F Benedetti","year":"2004","unstructured":"Benedetti, F. et al. Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res. Bull. 63, 203\u2013211 (2004).","journal-title":"Brain Res. Bull."},{"key":"1021_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archpsyc.1965.01720340008002","volume":"12","author":"LC Park","year":"1965","unstructured":"Park, L. C. & Covi, L. Nonblind placebo trial: an exploration of neurotic patients\u2019 responses to placebo when its inert content is disclosed. Arch. Gen. Psychiatry 12, 36\u201345 (1965).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1021_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015591","volume":"5","author":"TJ Kaptchuk","year":"2010","unstructured":"Kaptchuk, T. J. et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE\u00a05, e15591 (2010).","journal-title":"PLoS ONE"},{"key":"1021_CR82","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/j.pain.0000000000000566","volume":"157","author":"L Colloca","year":"2016","unstructured":"Colloca, L., Enck, P. & DeGrazia, D. Relieving pain using dose-extending placebos: a scoping review. Pain 157, 1590\u20131598 (2016).","journal-title":"Pain"},{"key":"1021_CR83","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.mehy.2012.09.017","volume":"79","author":"P Enck","year":"2012","unstructured":"Enck, P., Grundy, D. & Klosterhalfen, S. A novel placebo-controlled clinical study design without ethical concerns \u2014 the free choice paradigm. Med. Hypotheses 79, 880\u2013882 (2012).","journal-title":"Med. Hypotheses"},{"key":"1021_CR84","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000069738","volume":"72","author":"M Fava","year":"2003","unstructured":"Fava, M., Evins, A. E., Dorer, D. J. & Schoenfeld, D. A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother. Psychosom. 72, 115\u2013127 (2003).","journal-title":"Psychother. Psychosom."},{"key":"1021_CR85","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pain.2008.07.027","volume":"139","author":"R Staud","year":"2008","unstructured":"Staud, R. & Price, D. D. Role of placebo factors in clinical trials with special focus on enrichment designs. Pain 139, 479\u2013480 (2008).","journal-title":"Pain"},{"key":"1021_CR86","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/archinte.164.6.597","volume":"164","author":"D Wendler","year":"2004","unstructured":"Wendler, D. & Miller, F. G. Deception in the pursuit of science. Arch. Intern. Med. 164, 597\u2013600 (2004).","journal-title":"Arch. Intern. Med."},{"key":"1021_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0304-3959(01)00296-2","volume":"93","author":"A Pollo","year":"2001","unstructured":"Pollo, A. et al. Response expectancies in placebo analgesia and their clinical relevance. Pain 93, 77\u201384 (2001).","journal-title":"Pain"},{"key":"1021_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000932","volume":"6","author":"L Colloca","year":"2021","unstructured":"Colloca, L. et al. Veteran engagement in opioid tapering research: a mission to optimize pain management. Pain Rep. 6, e932 (2021).","journal-title":"Pain Rep."},{"key":"1021_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archpsyc.1965.01720340008002","volume":"12","author":"L Park","year":"1965","unstructured":"Park, L. & TRIAL, C. L. N. P. An exploration of neurotic patients\u2019responses to placebo when its inert content is disclosed. Arch. Gen. Psychiatry 12, 36\u201345 (1965).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1021_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050201","volume":"5","author":"NS Young","year":"2008","unstructured":"Young, N. S., Ioannidis, J. P. & Al-Ubaydli, O. Why current publication practices may distort science. PLoS Med. 5, e201 (2008).","journal-title":"PLoS Med."},{"key":"1021_CR91","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1073\/pnas.1618569114","volume":"114","author":"D Fanelli","year":"2017","unstructured":"Fanelli, D., Costas, R. & Ioannidis, J. P. Meta-assessment of bias in science. Proc. Natl Acad. Sci. USA 114, 3714\u20133719 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1021_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/470437a","volume":"470","author":"J Schooler","year":"2011","unstructured":"Schooler, J. Unpublished results hide the decline effect. Nature 470, 437\u2013437 (2011).","journal-title":"Nature"},{"key":"1021_CR93","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013\u20132015. Nat. Rev. Drug Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1021_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamapsychiatry.2021.3204","volume":"79","author":"AJ Scott","year":"2022","unstructured":"Scott, A. J., Sharpe, L., Quinn, V. & Colagiuri, B. Association of single-blind placebo run-in periods with the placebo response in randomized clinical trials of antidepressants: a systematic review and meta-analysis. JAMA Psychiatry 79, 42\u201349 (2022).","journal-title":"JAMA Psychiatry"},{"key":"1021_CR95","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/bs.irn.2018.07.021","volume":"139","author":"MJ Coleshill","year":"2018","unstructured":"Coleshill, M. J., Sharpe, L., Colloca, L., Zachariae, R. & Colagiuri, B. Placebo and active treatment additivity in placebo analgesia: research to date and future directions. Int. Rev. Neurobiol. 139, 407\u2013441 (2018).","journal-title":"Int. Rev. Neurobiol."},{"key":"1021_CR96","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1740774510367916","volume":"7","author":"B Colagiuri","year":"2010","unstructured":"Colagiuri, B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin. Trials 7, 246\u2013255 (2010).","journal-title":"Clin. Trials"},{"key":"1021_CR97","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13196","volume":"3","author":"J Vollert","year":"2020","unstructured":"Vollert, J. et al. Assessment of placebo response in objective and subjective outcome measures in rheumatoid arthritis clinical trials. JAMA Netw. Open\u00a03, e2013196 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1021_CR98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1103319","volume":"365","author":"ME Wechsler","year":"2011","unstructured":"Wechsler, M. E. et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N. Engl. J. Med. 365, 119\u2013126 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/M18-3667","volume":"172","author":"DM Kent","year":"2020","unstructured":"Kent, D. M. et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann. Intern. Med. 172, 35\u201345 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1021_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","volume":"322","author":"TJ Schnitzer","year":"2019","unstructured":"Schnitzer, T. J. et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. J. Am. Med. Assoc. 322, 37\u201348 (2019).","journal-title":"J. Am. Med. Assoc."},{"key":"1021_CR101","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","volume":"79","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum, F. et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. 79, 800\u2013810 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1021_CR102","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cpt.31","volume":"97","author":"L Vase","year":"2015","unstructured":"Vase, L., Amanzio, M. & Price, D. D. Nocebo vs. placebo: the challenges of trial design in analgesia research. Clin. Pharmacol. Ther. 97, 143\u2013150 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1021_CR103","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.07.026","volume":"146","author":"DL Morton","year":"2009","unstructured":"Morton, D. L., Watson, A., El-Deredy, W. & Jones, A. K. Reproducibility of placebo analgesia: effect of dispositional optimism. Pain 146, 194\u2013198 (2009).","journal-title":"Pain"},{"key":"1021_CR104","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/j.pain.0000000000000217","volume":"156","author":"L Vase","year":"2015","unstructured":"Vase, L. et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain 156, 1795\u20131802 (2015).","journal-title":"Pain"},{"key":"1021_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04607-5","volume":"21","author":"TA Lang","year":"2020","unstructured":"Lang, T. A. & Stroup, D. F. Who knew? The misleading specificity of \u201cdouble-blind\u201d and what to do about it. Trials 21, 697 (2020).","journal-title":"Trials"},{"key":"1021_CR106","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood, L. et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Br. Med. J. 336, 601\u2013605 (2008).","journal-title":"Br. Med. J."},{"key":"1021_CR107","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1525\/maq.2000.14.1.51","volume":"14","author":"DE Moerman","year":"2000","unstructured":"Moerman, D. E. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure. Med. Anthropol. Q. 14, 51\u201372 (2000).","journal-title":"Med. Anthropol. Q."},{"key":"1021_CR108","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1359105320948588","volume":"27","author":"CR Blease","year":"2022","unstructured":"Blease, C. R. et al. Sharing clinical notes, and placebo and nocebo effects: can documentation affect patient health? J. Health Psychol. 27, 135\u2013146 (2022).","journal-title":"J. Health Psychol."},{"key":"1021_CR109","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16910","volume":"2","author":"MK Garcia","year":"2019","unstructured":"Garcia, M. K. et al. Effect of true and sham acupuncture on radiation-induced xerostomia among patients with head and neck cancer: a randomized clinical trial. JAMA Netw. Open 2, e1916910 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1021_CR110","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16929","volume":"2","author":"M Karst","year":"2019","unstructured":"Karst, M. & Li, C. Acupuncture\u2014a question of culture. JAMA Netw. Open 2, e1916929 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1021_CR111","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.299.9.1016","volume":"299","author":"RL Waber","year":"2008","unstructured":"Waber, R. L., Shiv, B., Carmon, Z. & Ariely, D. Commercial features of placebo and therapeutic efficacy. J. Am. Med. Assoc. 299, 1016\u20131017 (2008).","journal-title":"J. Am. Med. Assoc."},{"key":"1021_CR112","doi-asserted-by":"publisher","first-page":"218ra215","DOI":"10.1126\/scitranslmed.3006175","volume":"6","author":"S Kam-Hansen","year":"2014","unstructured":"Kam-Hansen, S. et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci. Transl Med. 6, 218ra215 (2014).","journal-title":"Sci. Transl Med."},{"key":"1021_CR113","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1037\/hea0000282","volume":"35","author":"K Faasse","year":"2016","unstructured":"Faasse, K., Martin, L. R., Grey, A., Gamble, G. & Petrie, K. J. Impact of brand or generic labeling on medication effectiveness and side effects. Health Psychol. 35, 187\u2013190 (2016).","journal-title":"Health Psychol."},{"key":"1021_CR114","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1001\/jamainternmed.2013.10391","volume":"173","author":"K Meissner","year":"2013","unstructured":"Meissner, K. et al. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern. Med. 173, 1941\u20131951 (2013).","journal-title":"JAMA Intern. Med."},{"key":"1021_CR115","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/bioe.12245","volume":"30","author":"C Blease","year":"2016","unstructured":"Blease, C., Colloca, L. & Kaptchuk, T. J. Are open-label placebos ethical? Informed consent and ethical equivocations. Bioethics 30, 407\u2013414 (2016).","journal-title":"Bioethics"},{"key":"1021_CR116","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1097\/j.pain.0000000000002234","volume":"162","author":"A Lembo","year":"2021","unstructured":"Lembo, A. et al. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain 162, 2428\u20132435 (2021).","journal-title":"Pain"},{"key":"1021_CR117","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapediatrics.2021.5750","volume":"176","author":"S Nurko","year":"2022","unstructured":"Nurko, S. et al. Effect of open-label placebo on children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized clinical trial. JAMA Pediatrics 176, 349\u2013356 (2022).","journal-title":"JAMA Pediatrics"},{"key":"1021_CR118","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1097\/j.pain.0000000000000700","volume":"157","author":"C Carvalho","year":"2016","unstructured":"Carvalho, C. et al. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain 157, 2766\u20132772 (2016).","journal-title":"Pain"},{"key":"1021_CR119","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/j.pain.0000000000002162","volume":"162","author":"C Carvalho","year":"2021","unstructured":"Carvalho, C. et al. Open-label placebo for chronic low back pain: a 5-year follow-up. Pain 162, 1521\u20131527 (2021).","journal-title":"Pain"},{"key":"1021_CR120","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000337053","volume":"81","author":"JM Kelley","year":"2012","unstructured":"Kelley, J. M., Kaptchuk, T. J., Cusin, C., Lipkin, S. & Fava, M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother. Psychosom. 81, 312\u2013314 (2012).","journal-title":"Psychother. Psychosom."},{"key":"1021_CR121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000447242","volume":"85","author":"M Schaefer","year":"2016","unstructured":"Schaefer, M., Harke, R. & Denke, C. Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial. Psychother. Psychosom. 85, 373\u2013374 (2016).","journal-title":"Psychother. Psychosom."},{"key":"1021_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20993-y","volume":"8","author":"TW Hoenemeyer","year":"2018","unstructured":"Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S. & Fontaine, K. R. Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial. Sci. Rep. 8, 2784 (2018).","journal-title":"Sci. Rep."},{"key":"1021_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77255-z","volume":"10","author":"Y Pan","year":"2020","unstructured":"Pan, Y. et al. Open-label placebos for menopausal hot flushes: a randomized controlled trial. Sci. Rep. 10, 20090 (2020).","journal-title":"Sci. Rep."},{"key":"1021_CR124","doi-asserted-by":"publisher","first-page":"853497","DOI":"10.3389\/fpsyt.2022.853497","volume":"13","author":"E Olliges","year":"2022","unstructured":"Olliges, E. et al. Open-label placebo administration decreases pain in elderly patients with symptomatic knee osteoarthritis \u2014 a randomized controlled trial. Front. Psychiatry 13, 853497 (2022).","journal-title":"Front. Psychiatry"},{"key":"1021_CR125","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/PSY.0b013e3181cbd38b","volume":"72","author":"R Ader","year":"2010","unstructured":"Ader, R. et al. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom. Med. 72, 192\u2013197 (2010).","journal-title":"Psychosom. Med."},{"key":"1021_CR126","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000828","volume":"5","author":"L Morales-Quezada","year":"2020","unstructured":"Morales-Quezada, L. et al. Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control. Pain Rep. 5, e828 (2020).","journal-title":"Pain Rep."},{"key":"1021_CR127","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2214.2007.00797.x","volume":"34","author":"AD Sandler","year":"2008","unstructured":"Sandler, A. D. & Bodfish, J. W. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 34, 104\u2013110 (2008).","journal-title":"Child Care Health Dev."},{"key":"1021_CR128","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.sleep.2015.06.015","volume":"16","author":"M Perlis","year":"2015","unstructured":"Perlis, M. et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. Sleep Med. 16, 1160\u20131168 (2015).","journal-title":"Sleep Med."},{"key":"1021_CR129","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000126074","volume":"77","author":"MU Goebel","year":"2008","unstructured":"Goebel, M. U., Meykadeh, N., Kou, W., Schedlowski, M. & Hengge, U. R. Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother. Psychosom. 77, 227\u2013234 (2008).","journal-title":"Psychother. Psychosom."},{"key":"1021_CR130","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1073\/pnas.1720548115","volume":"115","author":"J Kirchhof","year":"2018","unstructured":"Kirchhof, J. et al. Learned immunosuppressive placebo responses in renal transplant patients. Proc. Natl Acad. Sci. USA 115, 4223\u20134227 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1021_CR131","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1098\/rstb.2010.0399","volume":"366","author":"L Colloca","year":"2011","unstructured":"Colloca, L. & Miller, F. G. Harnessing the placebo effect: the need for translational research. Phil. Trans. R. Soc. B 366, 1922\u20131930 (2011).","journal-title":"Phil. Trans. R. Soc. B"},{"key":"1021_CR132","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tips.2011.12.001","volume":"33","author":"BK Doering","year":"2012","unstructured":"Doering, B. K. & Rief, W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol. Sci. 33, 165\u2013172 (2012).","journal-title":"Trends Pharmacol. Sci."},{"key":"1021_CR133","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3923","volume":"12","author":"P Enck","year":"2013","unstructured":"Enck, P., Bingel, U., Schedlowski, M. & Rief, W. The placebo response in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov. 12, 191\u2013204 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1021_CR134","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1523\/JNEUROSCI.3330-07.2007","volume":"27","author":"F Benedetti","year":"2007","unstructured":"Benedetti, F., Pollo, A. & Colloca, L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions. J. Neurosci. 27, 11934\u201311939 (2007).","journal-title":"J. Neurosci."},{"key":"1021_CR135","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1523\/JNEUROSCI.19-01-00484.1999","volume":"19","author":"M Amanzio","year":"1999","unstructured":"Amanzio, M. & Benedetti, F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 19, 484\u2013494 (1999).","journal-title":"J. Neurosci."},{"key":"1021_CR136","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0269881109104848","volume":"24","author":"JY Guo","year":"2010","unstructured":"Guo, J. Y., Wang, J. Y. & Luo, F. Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. J. Psychopharmacol. 24, 1561\u20131567 (2010).","journal-title":"J. Psychopharmacol."},{"key":"1021_CR137","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pain.2006.04.005","volume":"124","author":"L Colloca","year":"2006","unstructured":"Colloca, L. & Benedetti, F. How prior experience shapes placebo analgesia. Pain 124, 126\u2013133 (2006).","journal-title":"Pain"},{"key":"1021_CR138","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neuroscience.2012.04.066","volume":"217","author":"M Fiorio","year":"2012","unstructured":"Fiorio, M. et al. Enhancing non-noxious perception: behavioural and neurophysiological correlates of a placebo-like manipulation. Neuroscience 217, 96\u2013104 (2012).","journal-title":"Neuroscience"},{"key":"1021_CR139","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuroscience.2013.11.033","volume":"258","author":"M Fiorio","year":"2014","unstructured":"Fiorio, M., Recchia, S., Corra, F. & Tinazzi, M. Behavioural and neurophysiological investigation of the influence of verbal suggestion on tactile perception. Neuroscience 258, 332\u2013339 (2014).","journal-title":"Neuroscience"},{"key":"1021_CR140","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pain.2006.08.025","volume":"128","author":"R Klinger","year":"2007","unstructured":"Klinger, R., Soost, S., Flor, H. & Worm, M. Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain 128, 31\u201339 (2007).","journal-title":"Pain"},{"key":"1021_CR141","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5694\/mja2.12109","volume":"210","author":"S Adie","year":"2019","unstructured":"Adie, S., Harris, I., Chuan, A., Lewis, P. & Naylor, J. M. Selecting and optimising patients for total knee arthroplasty. Med. J. Aust. 210, 135\u2013141 (2019).","journal-title":"Med. J. Aust."},{"key":"1021_CR142","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.bja.2021.04.017","volume":"127","author":"J Quinlan","year":"2021","unstructured":"Quinlan, J., Levy, N., Lobo, D. N. & Macintyre, P. E. Preoperative opioid use: a modifiable risk factor for poor postoperative outcomes. Br. J. Anaesth. 127, 327\u2013331 (2021).","journal-title":"Br. J. Anaesth."},{"key":"1021_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01179-5","volume":"11","author":"B Ravi","year":"2021","unstructured":"Ravi, B. et al. Patterns of pre-operative opioid use affect the risk for complications after total joint replacement. Sci. Rep. 11, 22124 (2021).","journal-title":"Sci. Rep."},{"key":"1021_CR144","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11926-020-00929-0","volume":"22","author":"C Shadbolt","year":"2020","unstructured":"Shadbolt, C. et al. Opioid use and total joint replacement. Curr. Rheumatol. Rep. 22, 58 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1021_CR145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15265161.2015.1074314","volume":"15","author":"L Colloca","year":"2015","unstructured":"Colloca, L. Informed consent: hints from placebo and nocebo research. Am. J. Bioeth. 15, 17\u201319 (2015).","journal-title":"Am. J. Bioeth."},{"key":"1021_CR146","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11017-011-9179-8","volume":"32","author":"FG Miller","year":"2011","unstructured":"Miller, F. G. & Colloca, L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. Theor. Med. Bioeth. 32, 229\u2013243 (2011).","journal-title":"Theor. Med. Bioeth."},{"key":"1021_CR147","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11606-011-1977-1","volume":"27","author":"H Brody","year":"2012","unstructured":"Brody, H., Colloca, L. & Miller, F. G. The placebo phenomenon: implications for the ethics of shared decision-making. J. Gen. Intern. Med. 27, 739\u2013742 (2012).","journal-title":"J. Gen. Intern. Med."},{"key":"1021_CR148","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphar.2019.00167","volume":"10","author":"K Barnes","year":"2019","unstructured":"Barnes, K. et al. Can positive framing reduce nocebo side effects? Current evidence and recommendation for future research. Front. Pharmacol. 10, 167 (2019).","journal-title":"Front. Pharmacol."},{"key":"1021_CR149","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/hast.222","volume":"43","author":"H Brody","year":"2013","unstructured":"Brody, H. & Colloca, L. Patient autonomy and provider beneficence are compatible. Hastings Cent. Rep. 43, 6 (2013).","journal-title":"Hastings Cent. Rep."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01021-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:02:48Z","timestamp":1695387768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01021-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":149,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01021-4","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"3 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}